# A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Source: https://onco.cc/trials/nct07570823/  
OnCo record `nct07570823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SCTB35 in diffuse large B-cell lymphoma, now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT07570823, led by Sinocelltech, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Planned enrolment is 101 participants (estimated). The study started in 2026-06-04 and primary completion is expected in 2027-11. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07570823
- Phase: 3
- Setting: A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Sponsor: Sinocelltech
- Enrolled: 101

## Sources

- ClinicalTrials.gov NCT07570823: https://clinicaltrials.gov/study/NCT07570823

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [SCTB35](https://onco.cc/drugs/sctb35/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)

---
JSON: https://onco.cc/api/v1/entities/nct07570823.json